NIH plans a milestone-driven award supporting planning and early to definitive clinical trials across biomedical and other interventions for up to 7 years; applications are not yet being accepted.
NHLBI plans to fund single-site clinical trials (R61/R33) testing therapeutic, behavioral, or prevention strategies, encouraging innovative designs.
Supporting essential pilot studies for NHLBI clinical trials, aiming to inform Phase II-IV trial planning for heart, lung, blood, and sleep disorders.
NIH will fund investigator-initiated multi-site or decentralized clinical trials relevant to its mission, supporting planning and implementation over up to 7 years using a milestone-driven UG3/UH3 grant mechanism.
NIH's R21 grant supports early-stage, high-risk clinical trial research with potential for breakthroughs in biomedical, behavioral, or clinical fields.
This grant funds early phase clinical trials testing natural products like botanicals, probiotics, and dietary supplements with strong scientific backing for further testing.